VIROFEND THERAPEUTICS S.L.
Contact information
- Immunology
- Oncology
ViroFend Therapeutics is a Spanish biotechnology company focused on developing next – generation oncolityc virotherapies for the treatment of refractory solid tumors, with a special focus on colorectal cancer.
Our mission is to transform cancer treatment trough the use of genetically engineered viruses capable of selectively targeting tumor cells while simultaneously stimulating an anti-tumor immune response.
The project is based on an exclusive license agreement with The Icahn School of Medicine al Mount Sinai (USA), combining leading academic science with an industrial development model established in Spain.
- Development of the lead oncolityc candidate VFT111, currently in advanced preclinical phase.
- Design and validation of GMP production processes for oncolityc viruses.
- Scientific, regulatory, and strategic consulting services in virotherapy and advanced biotechnology projects.
- Implementation plan for a pilot research plant (2026) dedicated to the development of new virotherapy lines.
a. Pharmaceutical and biotech companies, interested in licensing or co-development agreements.
b. CROs and CDMOs specialized in oncolityc viruses and GMP manufacturing.
c. Research center and hospital working in inmuno-oncology.
d. Investors focused on biotechnology (venture capital, family offices, corporate VC)
e. Collaborations in national and European R&D programs.